Amneal to buy a biosimilar company; Samsung Bio workers protest
THE SO WHAT
Amneal paying $375M upfront for a biosimilar maker is another sign that scale in manufacturing and distribution is becoming more valuable than single-asset discovery. If you’re a smaller therapeutics player, your exit story needs a clear angle on how you plug into these consolidation plays — not just clinical data.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureThe Godmother of Silicon Valley is helping launch an AI healthcare residency program
An AI healthcare “residency” for startup co-founders is an admission that founder conflict — not tech — is the failure mode in this vertical. If you’re backing or building in AI + health, treat team dynamics and regulatory literacy as first-class diligence items, not soft factors you’ll fix later.
Startups & VentureGrab a ticket today: The first StrictlyVC of 2026 kicks off in just a week in San Francisco
Operator reality: the real value of a StrictlyVC room is not the panels, it’s seeing where capital is actually rotating in 2026 — infra, agents, or something else. If you’re fundraising or allocating, treat this as live market research and adjust your narrative based on what LPs and GPs are actually chasing, not what they tweet about.
Anthropic's valuation has hit $1T on Forge Global, a leading private marketplace exchange, surpassing OpenAI's valuation on the platform of $880B (Ben Bergman/Business Insider)
Anthropic trading at a $1T implied valuation on Forge Global — above OpenAI’s $880B there — shows private markets are now pricing AI labs like sovereign infra, not startups. For operators, that means your vendor risk, pricing power, and partnership leverage with model providers are shifting fast — treat these labs like quasi-utilities in your strategy, not interchangeable APIs.
Startups & VentureCloudsmith, which is building a cloud-native system to manage software artifacts, raised a $72M Series C, following a $23M Series B in 2025 (Natalie Breymeyer/Axios)
Artifact management just pulled a $72M Series C — the market is pricing software supply chain as a first-class risk surface, not a DevOps afterthought. If you’re rolling your own package repos in 2026, you’re implicitly accepting security and compliance liability your board doesn’t understand yet.